XNAS · Healthcare · Biotechnology
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -0.49 | -0.63 | -27.55% | $266,845 | ❌ Miss | -0.46% | -14.03% | — |
| 2026-03-03 | Q4 2025 | -0.43 | -0.53 | -23.26% | $514,161 | ✅ Beat | +2.93% | +3.92% | -3.41% |
| 2025-11-10 |
| Q3 2025 |
| -0.50 |
| -0.40 |
| +20.00% |
| $303,761 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-21 | Q2 2025 | -0.53 | -0.57 | -7.55% | $307,416.8 | mixed | +0.31% | -8.15% | -6.63% |
| 2025-03-11 | Q4 2024 | -0.38 | -0.76 | -100.00% | $3,419 | ❌ Miss | +2.39% | +3.10% | -12.23% |
| 2024-11-07 | Q3 2024 | -0.57 | -0.55 | +3.51% | $249,538 | ✅ Beat | -3.10% | -12.44% | -2.62% |
| 2024-08-27 | Q2 2024 | -0.47 | -0.56 | -19.15% | $270,887 | ❌ Miss | +1.51% | +0.76% | +1.76% |
| 2024-05-08 | Q1 2024 | -0.41 | -0.50 | -21.95% | $254,061 | ❌ Miss | -3.27% | -2.91% | -4.20% |
Showing last 8 quarters.